ECONOMIC BURDEN OF ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS HARBORING KRASG12C MUTATION IN SPAIN

被引：0
|
作者：
Fernandez-Barcelo, C. [1 ]
Abbas, I
Botella, X. [2 ]
Aguilo Domingo, M. [2 ]
Cots, F. [3 ]
Siles Cuesta, C. [3 ]
Arriola, E. [3 ]
Gas Lopez, M. E. [4 ]
Lopez Gomez, C. [4 ]
Juan-Vidal, O. [5 ]
Planellas, L. [6 ]
Lloansi, A. [6 ]
Sanchez, J. [1 ]
Reguart, N. [1 ]
Sampietro-Colom, L. [1 ]
机构：
[1] Hosp Clin Barcelona, Barcelona, Spain
[2] Consorci Sanitari Terrassa, Terrassa, Spain
[3] Hosp Mar CIBERONC, Barcelona, Spain
[4] Hlth Res Inst Hosp La Fe, Valencia, Spain
[5] Hosp La Fe Valencia, Valencia, Spain
[6] Amgen SA, Barcelona, Spain
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
RWD89
引用
收藏
页码：S521 / S521
页数：1
相关论文
共 50 条
  • [21] Efficacy and toxicity of drugs targeting KRASG12C mutation in non-small cell lung cancer: a meta-analysis
    Luo, Wei
    Zhu, Jing
    Zhang, Wenxue
    Yu, Airu
    Zhou, Wei
    Xu, Ke
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (12) : 1295 - 1303
  • [22] KRASG12C mutation-induced TOPK overexpression contributes to tumour progression in non-small cell lung cancer
    Cai, Chang
    Yao, Shuo
    Zou, Yanmei
    Lu, Hui
    Chen, Xiuqiong
    Wang, Yali
    Zheng, Kun
    Zhu, Feng
    Wang, Yihua
    Xiong, Hua
    Zhu, Junfei
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2023, 27 (12) : 1637 - 1652
  • [23] Spotlight on Sotorasib (AMG 510) for KRASG12C Positive Non-Small Cell Lung Cancer
    Zhang, Shannon S.
    Nagasaka, Misako
    LUNG CANCER-TARGETS AND THERAPY, 2021, 12 : 115 - 122
  • [24] Evaluation of KRASG12C inhibitor responses in novel murine KRASG12C lung cancer cell line models
    Sisler, Daniel J.
    Hinz, Trista K.
    Le, Anh T.
    Kleczko, Emily K.
    Nemenoff, Raphael A.
    Heasley, Lynn E.
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [25] Cetuximab in advanced non-small-cell lung cancer (NSCLC)
    Pirker, Robert
    LUNG CANCER, 2012, 77 : S13 - S14
  • [26] Activity and resistance to KRASG12C G12C inhibitors in non-small cell lung cancer and colorectal cancer
    Ye, Wei
    Lu, Xin
    Qiao, Yue
    Ou, Wen-Bin
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2024, 1879 (03):
  • [27] Safety, Efficacy, and Pharmacokinetics of AMG 510, a Novel KRASG12C Inhibitor, in Patients with Non-Small Cell Lung Cancer
    Govindan, R.
    Fakih, M.
    Price, T.
    Falchook, G.
    Desai, J.
    Kuo, J.
    Strickler, J.
    Krauss, J.
    Li, B.
    Denlinger, C.
    Durm, G.
    Ngang, J.
    Henary, H.
    Ngarmchamnanrith, G.
    Rasmussen, E.
    Morrow, P. K.
    Hong, D.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : S1125 - S1126
  • [28] A PREDICTIVE PATIENT-LEVEL SURROGACY MODEL BETWEEN PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS WITH PRE-TREATED ADVANCED OR METASTATIC (A/M) NON-SMALL-CELL LUNG CANCER (NSCLC) WITH A KRASG12C MUTATION
    Berardi, A.
    Maciel, D.
    Cope, S.
    Mastikhina, L.
    Lee, A.
    VALUE IN HEALTH, 2024, 27 (12)
  • [29] Adagrasib: a novel inhibitor for KRASG12C-mutated non-small-cell lung cancer
    Guo, Matthew Z.
    Marrone, Kristen A.
    Spira, Alexander
    Rosner, Samuel
    FUTURE ONCOLOGY, 2023, 19 (15) : 1037 - 1051
  • [30] Tackling KRASG12C-mutated non-small-cell lung cancer: iteration and exploration
    Luo, Jia
    Villaruz, Liza C.
    LANCET RESPIRATORY MEDICINE, 2024, 12 (08) : 576 - 577
12345